Novo Nordisk A/S

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: DK0062498333
DKK
309.60
246.82 (393.15%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

5.37 M

Shareholding (Mar 2024)

FII

0.05%

Held by 13 FIIs

DII

99.95%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

DKK 1,040,939 Million ()

stock-summary
P/E

11.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

3.79%

stock-summary
Debt Equity

-0.23

stock-summary
Return on Equity

61.08%

stock-summary
Price to Book

6.13

Revenue and Profits:
Net Sales:
76,857 Million
(Quarterly Results - Jun 2025)
Net Profit:
26,503 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
379.26%
0%
379.26%
6 Months
374.85%
0%
374.85%
1 Year
454.44%
0%
454.44%
2 Years
621.34%
0%
621.34%
3 Years
524.45%
0%
524.45%
4 Years
793.51%
0%
793.51%
5 Years
477.72%
0%
477.72%

Novo Nordisk A/S for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
19.93%
EBIT Growth (5y)
19.86%
EBIT to Interest (avg)
18.19
Debt to EBITDA (avg)
0.11
Net Debt to Equity (avg)
0.56
Sales to Capital Employed (avg)
1.66
Tax Ratio
20.93%
Dividend Payout Ratio
50.28%
Pledged Shares
0
Institutional Holding
0.03%
ROCE (avg)
84.59%
ROE (avg)
69.89%
Valuation key factors
Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
7.38
EV to EBIT
9.13
EV to EBITDA
8.22
EV to Capital Employed
5.32
EV to Sales
4.24
PEG Ratio
0.47
Dividend Yield
3.18%
ROCE (Latest)
58.27%
ROE (Latest)
66.09%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 13 Foreign Institutions (0.05%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 12.93% vs 25.34% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 32.18% vs 3.20% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "76,857.00",
          "val2": "68,060.00",
          "chgp": "12.93%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "38,305.00",
          "val2": "34,374.00",
          "chgp": "11.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "4,958.00",
          "val2": "1,562.00",
          "chgp": "217.41%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "26,503.00",
          "val2": "20,050.00",
          "chgp": "32.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "435.50%",
          "val2": "375.10%",
          "chgp": "6.04%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 25.03% vs 31.26% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 20.68% vs 50.71% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "290,403.00",
          "val2": "232,261.00",
          "chgp": "25.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "147,948.00",
          "val2": "111,383.00",
          "chgp": "32.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1,929.00",
          "val2": "739.00",
          "chgp": "161.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-6,204.00",
          "val2": "-70.00",
          "chgp": "-8,762.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "100,988.00",
          "val2": "83,683.00",
          "chgp": "20.68%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "480.00%",
          "val2": "445.10%",
          "chgp": "3.49%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
76,857.00
68,060.00
12.93%
Operating Profit (PBDIT) excl Other Income
38,305.00
34,374.00
11.44%
Interest
4,958.00
1,562.00
217.41%
Exceptional Items
0.00
0.00
Consolidate Net Profit
26,503.00
20,050.00
32.18%
Operating Profit Margin (Excl OI)
435.50%
375.10%
6.04%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 12.93% vs 25.34% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 32.18% vs 3.20% in Jun 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
290,403.00
232,261.00
25.03%
Operating Profit (PBDIT) excl Other Income
147,948.00
111,383.00
32.83%
Interest
1,929.00
739.00
161.03%
Exceptional Items
-6,204.00
-70.00
-8,762.86%
Consolidate Net Profit
100,988.00
83,683.00
20.68%
Operating Profit Margin (Excl OI)
480.00%
445.10%
3.49%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 25.03% vs 31.26% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 20.68% vs 50.71% in Dec 2023

stock-summaryCompany CV
About Novo Nordisk A/S stock-summary
stock-summary
Novo Nordisk A/S
Pharmaceuticals & Biotechnology
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Company Coordinates stock-summary
Company Details
Novo Alle 1 , BAGSVAERD None : 2880
stock-summary
Tel: 45 44 44888845 3075 9085
stock-summary
Registrar Details